全球核黄疸治疗市场 – 行业趋势及 2030 年预测

核黄疸治疗市场分析及规模

全世界有 60% 至 80% 的新生儿患有黄疸。发达国家每 10 万名儿童中只有 0.4 至 2.7 名患有核黄疸或急性胆红素脑病。当胆红素水平达到这一水平时，它们会扩散到大脑并损害中枢神经系统组织。目前，“核黄疸”是指黄疸造成的严重神经损伤。但所有由严重黄疸引起的损伤也被视为核黄疸的一种形式或阶段。

Data Bridge Market Research 分析，2022 年核黄疸治疗市场规模为 28.6 亿美元，预计到 2030 年将达到 34.8 亿美元，2023 年至 2030 年的复合年增长率为 2.50%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

核黄疸治疗市场范围和细分  

Market Definition

Kernicterus is a kind of brain damage that is carried by high bilirubin levels in a newborn's blood. The condition is frequently connected to newborns with severe, untreated jaundice. Hearing loss and athetoid cerebral palsy may result. In addition to cerebral deficits, kernicterus may result in visual and dental problems. Early detection and treatment of jaundice can prevent kernicterus.

Kernicterus Treatment Market Dynamics

Drivers

• Demand for managing hyperbilirubinemia risks in neonates underpins lucrative avenues that will propel the market growth

The health risks of untreated or improperly managed neonatal jaundice in newborns are considerable. As a result, bilirubin meters are in high demand in hospitals and infant care. Notably, improvements in detecting newborn hyperbilirubinemia have driven market participants' development prospects. Guidelines for managing newborns at risk are continually changing in developed countries, such as the U.K., which has accelerated growth potential. To address the demand for non-invasive bilirubin metres for newborns and babies, it is noteworthy that non-invasive transcutaneous bilirubin are heavily advocated. Much of the bilirubin meters market is driven by the growing usage of technologically advanced devices in emerging nations.

• Usage of exchange transfusion therapy in the cure of kernicterus treatment will propel the market growth

The immediate and effective method of clearing the blood of the already developed bilirubin. The procedure calls for removing the baby's blood, primarily the plasma, and replacing it with citrate phosphate dextrose (CPD) stored blood that is bilirubin-free. This condition is suggested when acute bilirubin encephalopathy symptoms are present and serum bilirubin levels remain high despite efforts to lower them. An exchange transfusion is typically used to treat serum bilirubin levels greater than 20–25 mg/dL. Use an erythrocyte concentrate that matches ABO type and is Rh-negative.

Opportunities

• Increased prevalence of kernicterus

The primary variables affecting the market growth rate are the increased prevalence of kernicterus. A total of 494 babies (320 boys; mean [SD] birth weight, 3505 [527] g) out of the 992 378 live babies (958 051 term births and 34 327 near-term births) had extreme hyperbilirubinemia (50 per 100,000 babies), 6.8 babies out of 100,000 had hazardous hyperbilirubinemia and 1.3 babies out of 100,000 had kernicterus. The prevalence of hypothyroidism and urinary tract infections is another factor that would moderate the market's development rate.

Moreover, during the forecast period of 2023-2030, the market for kernicterus treatments will benefit from the increase in R&D efforts and the emergence of new markets.

Restraints/Challenges

• Side effects of kernicterus treatment will hamper the market growth

An uncommon kind of brain damage can occur in neonates with jaundice. Infants with total serum bilirubin levels of more than 30 mg/dL are at an average risk of developing chronic kernicterus at a rate of roughly one in seven. Infants with bilirubin levels less than 25 mg/dL can also develop kernicterus, though it is unknown how often this condition is in the general population. These are the factors which hamper the market growth.

This kernicterus treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the kernicterus treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Kernicterus Treatment Market Scope

The kernicterus treatment market is segmented on the basis of treatment, diagnosis, symptoms, dosage, route of administration, end-users, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Phototherapy
• Intravenous Immunoglobulins (IVIG)
• Blood Transfusion
• Medication
• Others

 Diagnosis

• Physical Examination
• Bilirubin Blood Test
• Others

 Symptoms

• Jaundice
• Unusual Eye Movements
• Vomiting
• Fever
• Poor Feeding
• Apnoea
• Irritability
• Seizures
• Sleepiness
• Others

 Dosage

• Injection
• Solution
• Others

Route of Administration

• Oral
• Intravenous
• Others

End-Users

• Clinic
• Hospital
• Others

 Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Kernicterus Treatment Market Regional Analysis/Insights

对核黄疸治疗市场进行了分析，并按国家、治疗、诊断、症状、剂量、给药途径、最终用户、分销渠道提供了市场规模见解和趋势。

核黄疸治疗市场报告涵盖的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

北美在核黄疸治疗市场占据主导地位，因为该地区拥有大量知名参与者、高水平的可支配收入和先进的医疗保健系统。

由于政府援助扩大、医疗保健领域投资增加以及研发力度加大，预计亚太地区将在 2023 年至 2030 年的预测期内实现最高增长率。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

竞争格局和核黄疸治疗市场份额分析

核黄疸治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对核黄疸治疗市场的关注有关。

核黄疸治疗市场的一些主要参与者包括：

• 拜耳公司（德国）
• 百特（美国）
• 武田药品工业株式会社（日本）
• Grifols, SA（日本）
• CSL有限公司（澳大利亚）
• Kedrion SpA（意大利）
• Biotest AG（德国）
• 中国生物制品控股股份有限公司 (中国)
• Octapharma Brasil Ltda（瑞士）
• 辉瑞公司（美国）
• 诺华公司（瑞士）
• 赛诺菲（法国）
• 强生私人有限公司（美国）
• 雅培（美国）
• 葛兰素史克公司 (英国)
• Cipla Inc.（美国）

SKU-67350